EpiCor is perfectly suited for further formulation to achieve maximum clinical results due to the documented modes of action identified in peer-reviewed journals. All the published clinical research on EpiCor has been done on the basis of a daily dose of 500 mg. Embria encourages manufacturers to refer to the Embria document, "Biochemical Markers Observed in EpiCor Studies” to determine how best to complement the benefits of EpiCor with other ingredients.

« Back